1. Sarosh A. Janjua MD1, Sandra L. Cremers MD FACS1
Visual Outcomes After Implantation of 2 Different Intraocular Lens: AcrySof SA60AT and MemoryLens CV232
Sarosh A. Janjua MD1, Sandra L. Cremers MD FACS1
1. Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA

2. PURPOSE
To compare the differences in visual and surgical outcomes after implantation of AcrySof SA60AT lens versus MemoryLens CV232 lens.

3. METHODS
Study Design Retrospective cohort Population A database of 1800 phacoemulsifications performed by residents at the Massachusetts Eye and Ear Infirmary . Selection Criteria Patients were recruited in two groups : those that were implanted with SA60AT (727 eyes) and those that were implanted with CV232 (108 eyes) Exclusion Criteria Included any co-exitsing ocular pathology that might affect visual acuity, such as glaucoma, age-related macular degeneration and previous ocular surgery/trauma.

4. METHODS
A complete ophthalmological assessment was performed at 1 day, 1 week, 1, 3, 6-9, 12 and 18 months, and the findings were noted. A number of visual outcomes, including visual acuity in LogMAR units, were compared between the two groups, as well as surgical outcomes. Major confounders like history of glaucoma, diabetes, and previous ocular surgery, as well as the level of experience of the surgeon were controlled for statistically. The analysis was performed using STATA Version 9.

5. RESULTS
There was significantly greater improvement in best-corrected visual acuity (BCVA) with SA60AT lens than with CV232 at 3 months (p = 0.04), 6-9 months (p = 0.02), and 12 and 18 months (both p < 0.001). The rate of improvement in BCVA was significantly faster for SA60AT than for CV232 (p < 0.001). CV232 lens had a greater incidence of both posterior capsule opacification and YAG capsulotomy (both p <0.001).

6. Table 1. Characteristics of the Two Study Groups
SA60AT
CV232
P value
Number of Patients
557 90
Female/Male
314/243
46/44
0.36
Age, years
70.5 ± 12.5
70.6 ± 10.9
0.94
Number of Eyes OD OS
727
356 (49%)
371 (51%)
108
57 (53%)
51 (47%)
0.47
Glaucoma
17 (2.3%)
11 (10.2%)
<0.001*
Diabetes
146 (20.1%)
30 (27.8%)
0.08
Previous Ocular Surgery
59 (8.1%)
5 (4.6%)
0.25
Level of Surgeon
Resident
Attending
508 (70%)
219 (30%)
107 (99%)
1 (1%)
Outcomes
PCO noted
217 (29%)
44 (41%)
Median PCO grade 1
YAG
14 (1.9%)
14 (13.0%)
AC tear
11 (1.5%)
1 (0.9%)
0.99
PC tear
8 (7.4%)
0.01*†
Vitrectomy
6 (5.6%)
0.02*†
Reoperation
1 (0.1%)
0 (0%)
*Statistically significant by Fisher’s exact test.
†No significant group differences were found for vitrectomy rates or posterior tears after controlling for level of the surgeon.

8. CONCLUSIONS
Patients implanted with SA60AT lens had greater and faster improvement in best-corrected visual acuity (BCVA) than those implanted with CV232 lens. Incidence of posterior capsule opacification (PCO) and YAG capsulotomy was higher for patients implanted with CV232.

9. FINANCIAL DISCLOSURES
None